

S1 Table. The changes of blastocyst development rate in the supplement with the different dosages of the kinase inhibitors [MEK inhibitor (PD98059), PI3K inhibitor (LY294002), JAK inhibitor (JAK I-II), and EGFR inhibitor (PD168393)].

Imhibitor	Untreated (n=46)	PD98059 ( $\mu$ M)					LY294002 ( $\mu$ M)					JAK I-II ( $\mu$ M)					PD168393 ( $\mu$ M)				
		500	100	50	10	0.1	100	50	20	10	1	1	0.1	0.01	0.001	10	2	1	0.1	0.01	
Two-cell	98.2	70.4	88.0	83.3	92.9	90.0	10.0 <sup>a</sup>	77.5	100.0	85.7	95.5	87.5	85.1	81.5	89.2	41.2 <sup>a</sup>	90.9	84.0	80.0	100.0	
Four-cell	91.2	18.5 <sup>a</sup>	76.0	75.0	85.7	90.0	10.0 <sup>a</sup>	60.0 <sup>a</sup>	81.5	75.0	90.9	68.8	70.2	55.6 <sup>a</sup>	64.9 <sup>a</sup>	29.4 <sup>a</sup>	84.8	72.0	73.3	78.6	
Morula	91.2	14.8 <sup>a</sup>	64.0 <sup>a</sup>	75.0	78.6	90.0	6.7 <sup>a</sup>	27.5 <sup>a</sup>	51.9 <sup>a</sup>	64.3 <sup>a</sup>	77.3	62.5 <sup>a</sup>	51.1 <sup>a</sup>	51.9 <sup>a</sup>	59.5 <sup>a</sup>	11.8 <sup>a</sup>	60.6 <sup>a</sup>	68.0 <sup>a</sup>	73.3	78.6	
Blastocyst	84.2	14.8 <sup>a</sup>	60.0 <sup>a</sup>	66.7 <sup>a</sup>	78.6	80.0	3.3 <sup>a</sup>	17.5 <sup>a</sup>	51.9 <sup>a</sup>	64.3 <sup>a</sup>	72.7	18.8 <sup>a</sup>	48.9 <sup>a</sup>	51.9 <sup>a</sup>	56.8 <sup>a</sup>	11.8 <sup>a</sup>	51.5 <sup>a</sup>	52.0 <sup>a</sup>	73.3	78.6	

<sup>a</sup>P<0.05 compared to blank group